• Home
• Our work with communities
• Global health programmes
• Lymphatic Filariasis

Lymphatic Filariasis

We are an active partner in one of the world’s biggest and boldest public health initiatives - the international, World Health Organization (WHO) led effort - to rid the world of the disfiguring and disabling tropical disease lymphatic filariasis (LF).

LF, a mosquito-transmitted disease is one of the principal causes of permanent disability globally and currently more than 120 million people in Asia, Africa and Latin America are affected.

As part of our commitment to eliminate LF, so far we have donated over one billion albendazole treatments to stop the transmission of this disease to 48 countries.. Our aim is to donate as much albendazole as required to treat the one billion people in 83 countries who are at risk from this disease.

As part of our commitment to eliminate LF, we have donated over one billion treatments to stop the transmission of this disease. In 2007, we donated 150 million albendazole tablets to 19 countries. Our aim is to donate as much albendazole as required to treat the one billion people in 83 countries who are at risk from this disease.

Our commitment does not stop with the donation of albendazole. We also provide grants and staff expertise to support the coalition-building, planning, training and communication activities of the Global Alliance to Eliminate LF.

The Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was officially formed in 2000. We are a founder member of the Alliance that now includes the Ministries of Health of LF-endemic countries and over 40 organisations from public and private sectors, academia, government bodies and non-governmental organisations: all committed to eliminating LF.

Find out more:

• About LF
• Living with LF
• Our commitment on LF
• Progress against LF
• Future for LF
• The Carter Center Event
• Partners and links
• Contact

Back to top